

SMPC FORMAT

Encifer (Iron Sucrose Injection USP 100mg/5ml)

1. NAME OF THE FINISHED PHARMACEUTICAL PRODUCT

Encifer (Iron Sucrose Injection USP 100mg/5ml)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 5 ml contains 100 mg iron as iron sucrose (iron(III)-hydroxide sucrose complex).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Encifer is indicated for the treatment of iron deficiency in the following indications:

- Where there is a clinical need for a rapid iron supply,
- In patients who cannot tolerate oral iron therapy or who are non-compliant,
- In active inflammatory bowel disease where oral iron preparations are ineffective,
- In chronic kidney disease when oral iron preparations are less effective.

The diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. Hb (haemoglobin), serum ferritin, TSAT (transferrin saturation), serum iron, etc.).

4.2 Posology and method of administration

Monitor carefully patients for signs and symptoms of hypersensitivity reactions during and following each administration of Encifer.

Encifer should only be administered when staff trained to evaluate and manage anaphylactic reactions is immediately available, in an environment where full resuscitation facilities can be assured. The patient should be observed for adverse effects for at least 30 minutes following each Encifer administration (see section 4.4).

Posology:

The cumulative dose of Encifer must be calculated for each patient individually and must not be exceeded.

Calculation of dosage

The total cumulative dose of Encifer, equivalent to the total iron deficit (mg), is determined by the haemoglobin level (Hb) and body weight (BW). The dose of Encifer must be individually calculated for each patient according to the total iron deficit calculated with the following Ganzoni formula, for example:

Total iron deficit [mg] = BW [kg] x (target Hb - actual Hb) [g/dl] x 2.4* + storage iron [mg]

- Below 35 kg BW: Target Hb = 13 g/dl and storage iron = 15 mg/kg BW
- 35 kg BW and above: Target Hb = 15 g/dl and storage iron = 500 mg

* Factor 2.4 = 0.0034 (iron content of Hb = 0.34%) x 0.07 (blood volume = 7% of BW) x 1000 (conversion of [g] to [mg]) x 10

Total Encifer to be administered (in ml) = Total iron deficit [mg] / 20 mg iron/ml

Total amount of Encifer (ml) to be administered according to body weight, actual Hb level and target Hb level*:

BW	Total amount of Encifer (20 mg iron per ml) to be administered			
	Hb 6.0 g/dl	Hb 7.5 g/dl	Hb 9.0 g/dl	Hb 10.5 g/dl
30 kg	47.5 ml	42.5 ml	37.5 ml	32.5 ml
35 kg	62.5 ml	57.5 ml	50 ml	45 ml
40 kg	67.5 ml	60 ml	55 ml	47.5 ml
45 kg	75 ml	65 ml	57.5 ml	50 ml
50 kg	80 ml	70 ml	60 ml	52.5 ml
55 kg	85 ml	75 ml	65 ml	55 ml
60 kg	90 ml	80 ml	67.5 ml	57.5 ml
65 kg	95 ml	82.5 ml	72.5 ml	60 ml
70 kg	100 ml	87.5 ml	75 ml	62.5 ml
75 kg	105 ml	92.5 ml	80 ml	65 ml
80 kg	112.5 ml	97.5 ml	82.5 ml	67.5 ml
85 kg	117.5 ml	102.5 ml	85 ml	70 ml
90 kg	122.5 ml	107.5 ml	90 ml	72.5 ml

*Below 35 kg body weight: Target Hb = 13 g/dl

35 kg BW and above: Target Hb = 15 g/dl

To convert Hb (mM) to Hb (g/dl), multiply the former by 1.6.

If the total necessary dose exceeds the maximum allowed single dose, then the administration must be divided.

Posology

Adults

5 - 10 ml of Encifer (100 - 200 mg iron) 1 to 3 times a week. For administration time and dilution ratio see "Method of administration".

Special population

In patients with liver dysfunction, parenteral iron should only be administered after careful risk/benefit assessment. Parenteral iron administration should be avoided in patients with hepatic dysfunction where iron overload is a precipitating factor, in particular Porphyria Cutanea Tarda (PCT). Careful monitoring of iron status is recommended to avoid iron overload.

Parenteral iron should be used with caution in the case of acute or chronic infection. It is recommended that the administration of Encifer is stopped in patients with bacteraemia. In patients with chronic infection, a risk/benefit evaluation should be performed.

4.3 Method of administration

Encifer must only be administered by the intravenous route. This may be by a slow intravenous injection, by an intravenous drip infusion or directly into the venous line of the dialysis machine.

Intravenous drip infusion

Encifer must only be diluted in sterile 0.9% m/V sodium chloride (NaCl) solution. Dilution must take place immediately prior to infusion and the solution should be administered as follows:

Encifer dose (mg of iron)	Encifer dose (ml of Encifer)	Maximum dilution volume of 0.9% m/V sterile NaCl solution	Minimum Infusion Time
50 mg	2.5 ml	50 ml	8 minutes
100 mg	5 ml	100 ml	15 minutes
200 mg	10 ml	200 ml	30 minutes

For stability reasons, dilutions to lower Encifer concentrations are not permissible

Intravenous injection

Encifer may be administered by slow intravenous injection at a rate of 1 ml undiluted solution per minute and not exceeding 10 ml Encifer (200 mg iron) per injection.

Injection into venous line of dialysis machine

Encifer may be administered during a haemodialysis session directly into the venous line of the dialysis machine under the same conditions as for intravenous injection.

Paravenous leakage must be avoided because leakage of iron sucrose at the injection site can lead to pain, inflammation and brown discoloration of the skin.

4.4 Contraindications

The use of iron sucrose is contraindicated in the following conditions:

- Hypersensitivity to the active substance, to iron sucrose or any of its excipients listed in section 6.1
- Known serious hypersensitivity to other parenteral iron products
- Anaemia not caused by iron deficiency
- Evidence of iron overload or hereditary disturbances in utilisation of iron.

4.5 Special warnings and precautions for use

Parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions. Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes including iron sucrose. There have been reports of hypersensitivity reactions which progressed to Kounis syndrome (acute allergic coronary arteriospasm that can result in myocardial infarction, see section 4.8). In several studies performed in patients who had a history of a hypersensitivity reaction to iron dextran or ferric gluconate, iron sucrose was shown to be well tolerated. For known serious hypersensitivity to other parenteral iron product, see section 4.3.

The risk of hypersensitivity reactions is enhanced for patients with known allergies including drug allergies, including patients with a history of severe asthma, eczema or other atopic allergy.

There is also an increased risk of hypersensitivity reactions to parenteral iron complexes in patients with immune or inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis).

Encifer should only be administered when staff trained to evaluate and manage anaphylactic reactions is immediately available, in an environment where full resuscitation facilities can be assured. Each patient should be observed for adverse effects for at least 30 minutes following each Encifer injection. If hypersensitivity reactions or signs of intolerance occur during administration, the treatment must be stopped immediately. Facilities for cardio respiratory resuscitation and equipment for handling acute anaphylactic/anaphylactoid reactions should be available, including an injectable 1:1000 adrenaline solution. Additional treatment with antihistamines and/or corticosteroids should be given as appropriate.

4.6 Paediatric population

The use of iron sucrose has not been adequately studied in children and, therefore, iron sucrose is not recommended for use in children.

4.7 Interaction with other medicinal products and other forms of interaction

As with all parenteral iron preparations, iron sucrose should not be administered concomitantly with oral iron preparations since the absorption of oral iron is reduced. Therefore, oral iron therapy should be started at least 5 days after the last injection of iron sucrose.

4.8 Additional information on special populations

In patients with liver dysfunction, parenteral iron should only be administered after careful risk/benefit assessment. Parenteral iron administration should be avoided in patients with hepatic dysfunction where iron overload is a precipitating factor, in particular Porphyria Cutanea Tarda (PCT). Careful monitoring of iron status is recommended to avoid iron overload.

Parenteral iron should be used with caution in the case of acute or chronic infection. It is recommended that the administration of Encifer is stopped in patients with bacteraemia. In patients with chronic infection, a risk/benefit evaluation should be performed.

4.9 Paediatric population

The use of iron sucrose has not been adequately studied in children and, therefore, iron sucrose is not recommended for use in children.

4.10 Fertility, pregnancy and lactation

4.10.1 General principles

A careful risk/benefit evaluation is required before use during pregnancy and Encifer should not be used during pregnancy unless clearly necessary.

4.10.2 Women of childbearing potential / Contraception in males and females

Iron deficiency anaemia occurring in the first trimester of pregnancy can in many cases be treated with oral iron. Treatment with Encifer should be confined to second and third trimester if the benefit is judged to outweigh the potential risk for both the mother and the foetus.

4.10.3 Pregnancy

There is no data from the use of iron sucrose in pregnant women in the first trimester. Data (303 pregnancy outcomes) from the use of iron sucrose in pregnant women in the second and third trimester showed no safety concerns for the mother or newborn.

Foetal bradycardia may occur following administration of parenteral irons. It is usually transient and a consequence of a hypersensitivity reaction in the mother. The unborn baby should be carefully monitored during intravenous administration of parenteral irons to pregnant women.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.

4.10.4 Breastfeeding

There is limited information on the excretion of iron in human milk following administration of intravenous iron sucrose. In one clinical study, 10 healthy breast-feeding mothers with iron deficiency received 100 mg iron in the form of iron sucrose. Four days after treatment, the iron content of the breast milk had not increased and there was no difference from the control group (n=5). It cannot be excluded that newborns/infants may be exposed to iron derived from iron sucrose via the mother's milk, therefore the risk/benefit should be assessed.

Preclinical data do not indicate direct or indirect harmful effects to the nursing child. In lactating rats treated with ⁵⁹Fe-labelled iron sucrose, low secretion of iron into the milk and transfer of iron into the offspring was observed. Non metabolised iron sucrose is unlikely to pass into the mother's milk.

4.10.5 Fertility

No effects of iron sucrose treatment were observed on fertility and mating performance in rats.

4.11 Effects on ability to drive and use machines

In the case of symptoms of dizziness, confusion or light headedness following the administration of iron sucrose, patients should not drive or use machinery until the symptoms have ceased.

4.12 Undesirable effects

a) Summary of the safety profile

The most commonly reported adverse drug reaction in clinical trials with iron sucrose was dysgeusia, which occurred with a rate of 4.5 events per 100 subjects. The most important serious adverse drug reactions associated with iron sucrose are hypersensitivity reactions, which occurred with a rate of 0.25 events per 100 subjects in clinical trials. Anaphylactoid/anaphylactic reactions were reported only in the post-marketing setting (estimated as rare); fatalities have been reported. See section 4.4. The adverse drug reactions reported after the administration of iron sucrose in 4,064 subjects in clinical trials as well as those reported from the post-marketing setting are presented in the table below.

b) Tabulated list of adverse reactions

System Organ Class	Common (≥1/100, <1/10)	Uncommon (≥1/1,000, <1/100)	Rare (≥1/10,000, <1/1,000)	Frequency not known¹⁾
Immune disorders		Hypersensitivity		Anaphylactoid/anaphylactic reactions, angioedema
Nervous disorders	Dysgeusia	Headache, dizziness, paraesthesia, hypoaesthesia	Syncope, somnolence	Depressed level of consciousness, confusional state, loss of consciousness, anxiety, tremor
Cardiac disorders			Palpitations	Bradycardia, tachycardia, Kounis syndrome
Vascular disorders	Hypotension, hypertension	Flushing, phlebitis		Circulatory collapse, thrombophlebitis
Respiratory, thoracic and		Dyspnoea		Bronchospasm

mediastinal disorders				
Renal and urinary disorders			Chromaturia	
Gastrointestinal disorders	Nausea	Vomiting, abdominal pain, diarrhoea, constipation		
Skin and subcutaneous tissue disorders		Pruritus, rash		Urticaria, erythema
Musculoskeletal and connective tissue disorders		Muscle spasm, myalgia, arthralgia, pain in extremity, back pain		
General disorders and administration site conditions	Injection/infusion site reaction ²⁾	Chills, asthenia, fatigue, oedema peripheral, pain	Chest pain, hyperdrosis, pyrexia	Cold sweat, malaise, pallor, influenza like illness ³⁾
Investigations		Alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, serum ferritin increased	Blood lactate dehydrogenase increased	

¹⁾ Spontaneous reports from the post-marketing setting; estimated as rare

²⁾ The most frequently reported are: injection/infusion site pain, -extravasation, -irritation, -reaction, -discolouration, -haematoma, -pruritus.

³⁾ Onset may vary from a few hours to several days.

4.13 Overdose

Overdose can cause iron overload which may manifest itself as haemosiderosis. Overdose should be treated, as deemed necessary by the treating physician, with an iron chelating agent or according to standard medical practice.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group and ATC code:

Pharmacotherapeutic group: Anti-anaemic preparation, iron, parenteral preparation, ATC code: B03AC.

Mechanism of action

Iron sucrose, the active ingredient of Encifer, is composed of a polynuclear iron(III)-hydroxide core surrounded by a large number of non-covalently bound sucrose molecules. The complex has a weight average molecular weight (Mw) of approximately 43 kDa. The polynuclear iron core has a structure similar to that of the core of the physiological iron storage protein ferritin. The complex is designed to provide, in a controlled manner, utilisable iron for the iron transport and storage proteins in the body (i.e., transferrin and ferritin, respectively).

Pharmacodynamic effects

Following intravenous administration, the polynuclear iron core from the complex is taken up predominantly by the reticuloendothelial system in the liver, spleen, and bone marrow. In a second step, the iron is used for the synthesis of Hb, myoglobin and other iron-containing enzymes, or stored primarily in the liver in the form of ferritin

Clinical Studies: Efficacy and safety

Chronic kidney disease

Study LU98001 was a single arm study to investigate the efficacy and safety of 100 mg iron as iron sucrose for up to 10 sessions over 3-4 weeks in haemodialysis patients with iron deficiency anaemia (Hb >8 and <11.0 g/dl, TSAT <20%, and serum ferritin ≤300 µg/l) who were receiving rHuEPO therapy. A Hb ≥11 g/dl was attained in 60/77 patients. The mean increase in serum ferritin and TSAT was significant from baseline to the end of treatment (Day 24) as well as to the 2 and 5-weeks follow-up visit.

Study 1VEN03027 was a randomised study comparing iron sucrose (1000 mg in divided doses over 14 days) and oral ferrous sulphate (325 mg 3 times daily for 56 days) in non-dialysis dependent chronic kidney disease patients (Hb ≤11.0 g/dl, serum ferritin ≤300 µg/l, and TSAT ≤25%) with or without rHuEPO. A clinical response (defined as Hb increase ≥1.0 g/dl and serum ferritin increase ≥160 µg/l) was more frequently observed in patients treated with iron sucrose (31/79; 39.2%) compared to oral iron (1/82; 1.2%); p<0.0001.

Inflammatory Bowel Disease

A randomized, controlled study compared iron sucrose (single IV dose of 200 mg iron once per week or every second week until the cumulative dose was reached) with oral iron (200 mg twice daily for 20 weeks) in patients with inflammatory bowel disease and anaemia (Hb <11.5 g/dl). At the end of treatment, 66% of patients in the iron sucrose group had an increase in Hb ≥2.0 g/dl compared to 47% in the oral iron group (p=0.07).

Postpartum

A randomized, controlled trial in women with postpartum iron deficiency anaemia (Hb <9 g/dl and serum ferritin <15 µg/l at 24–48 hours post-delivery) compared 2 × 200 mg iron given as iron sucrose on Days 2 and 4 (n=22) and 200 mg of oral iron given as ferrous sulphate twice daily for 6 weeks (n=21). The mean increase in Hb from baseline to Day 5 was 2.5 g/dl in the iron sucrose group and 0.7 g/dl in the oral iron group (p<0.01).

Pregnancy

In a randomized, controlled study, women in their third trimester of pregnancy with iron deficiency anaemia (Hb 8 to 10.5 g/dl and serum ferritin <13 µg/l) were randomised to iron sucrose (individually calculated total dose of iron administered over 5 days) or oral iron polymaltose complex (100 mg 3× daily until delivery). The increase in Hb from baseline was significantly greater in the iron sucrose group compared to the oral iron group at Day 28 and at delivery (p<0.01).

Paediatric population

The use of iron sucrose has not been adequately studied in children and, therefore, iron sucrose is not recommended for use in children.

5.2 Pharmacokinetic properties

Distribution

The ferrokinetics of iron sucrose labelled with ⁵²Fe and ⁵⁹Fe were assessed in 6 patients with anaemia and chronic renal failure. In the first 6–8 hours, ⁵²Fe was taken up by the liver, spleen and bone marrow. The radioactive uptake by the macrophage-rich spleen is considered to be representative of the reticuloendothelial iron uptake.

Following intravenous injection of a single 100 mg iron dose of iron sucrose in healthy volunteers, maximum total serum iron concentrations were attained 10 minutes after injection and had an average concentration of 538 µmol/l. The volume of distribution of the central compartment corresponded well to the volume of plasma (approximately 3 litres).

Biotransformation

Upon injection, sucrose largely dissociates and the polynuclear iron core is mainly taken up by the reticuloendothelial system of the liver, spleen, and bone marrow. At 4 weeks after administration, red cell iron utilization ranged from 59 to 97%.

Elimination

The iron sucrose complex has a weight average molecular weight (Mw) of approximately 43 kDa, which is sufficiently large to prevent renal elimination. Renal elimination of iron, occurring in the first 4 hours after injection of an iron sucrose dose of 100 mg iron, corresponded to less than 5% of the dose. After 24 hours, the total serum iron concentration was reduced to the pre-dose level. Renal elimination of sucrose was about 75% of the administered dose.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity, genotoxicity and toxicity to reproduction and development.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium Hydroxide

Water for Injection

6.2 Incompatibilities

NA

6.3 Shelf life

24 Months

6.4 Special precautions for storage

Store in a dark place 30 C. Do not freeze.

6.5 Nature and contents of container

5 ampules in one Alu/PVC blister pack. One such blister packed in carton

6.6 Special precautions for disposal and other handling

Ampoules or vials should be visually inspected for sediment and damage before use. Use only those containing a sediment free and homogenous solution.

Encifer must not be mixed with other medicinal products except sterile 0.9% m/V sodium chloride solution for dilution. For instructions on dilution of the product before administration, see section 4.2.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER AND MANUFACTURING SITE ADDRESSES

Marketing Authorization Holder

Emcure Pharmaceuticals Limited

Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C.,

Hinjawadi, Pune-411057, Maharashtra, India.

Manufacturing site:

Emcure Pharmaceuticals Ltd.

Plot No. J-174, J-168 & J-168/1,

MIDC, Tarapur, Boisar, Dist

Thane-401506, Maharashtra, India

8. MARKETING AUTHORISATION NUMBER

Rwanda FDA-HMP-MA-0860

9. DATE OF FIRST REGISTRATION/RENEWAL OF THE REGISTRATION

09/02/2024

10. DATE OF REVISION OF THE TEXT

23.05.2023